Nefopam and propoxyphene in episiotomy pain.
To evaluate relative efficacy, safety, and time course of analgesia, nefopam (45 and 90 mg), a new centrally acting nonnarcotic analgesic, was compared with propoxyphene (65 mg) and placebo in a single oral dose, parallel, stratified, randomized, double-blind trial with 100 hospitalized postpartum women with medium or severe episiotomy pain. Using subjective reports as indices of response, patients rated pain intensity and side effects at periodic interviews for 6 hr. After 45 and 90 mg nefopam, 21 of 25 and 20 of 25 patients (p less than 0.01) reported more than 50% reduction of pain, whereas after 65 mg propoxyphene 18 of 25 (p less than 0.05) and after placebo 11 of 25 reported reduction in pain. Relative efficacy, based on summed pain intensity differences, showed measurable but modest dose-dependent analgesia with nefopam, suggesting that the effectiveness of 65 mg propoxyphene lay between 45 mg nefopam and placebo. Side effects included mild dizziness and hypothermia after nefopam and mild elevation of diastolic arterial pressure after nefopam and propoxyphene. Our results suggest that 45- and 90-mg doses of nefopam induced more analgesia than 65 mg propoxyphene in the relief of episiotomy pain.
D000293:Adolescent; D000328:Adult; D011431:Dextropropoxyphene / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004341:Drug Evaluation; D004841:Episiotomy / Q000009:adverse effects*; D005260:Female; D006801:Humans; D009340:Nefopam / Q000009:adverse effects / Q000627:therapeutic use*; D010079:Oxazocines / Q000627:therapeutic use*; D010149:Postoperative Pain / Q000188:drug therapy*; D011247:Pregnancy; D011897:Random Allocation; D013997:Time Factors
D010079:Oxazocines; D009340:Nefopam; D011431:Dextropropoxyphene